These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 7904934)

  • 41. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.
    Buchanan LV; Kabell G; Brunden MN; Gibson JK
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):540-9. PubMed ID: 7505355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs.
    Sen L; Cui G; Sakaguchi Y; Singh BN
    J Pharmacol Exp Ther; 1998 May; 285(2):687-94. PubMed ID: 9580614
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction.
    Singh BN
    Am J Cardiol; 1990 Sep; 66(9):9C-20C. PubMed ID: 1699400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
    Scholz H
    Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antifibrillatory properties of the beta-adrenergic receptor antagonists, nadolol, sotalol, atenolol and propranolol, in the anesthetized dog.
    Patterson E; Lucchesi BR
    Pharmacology; 1984; 28(3):121-9. PubMed ID: 6144114
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications.
    Hohnloser SH; Singh BN
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):920-36. PubMed ID: 8548113
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A benefit-risk assessment of class III antiarrhythmic agents.
    Elming H; Brendorp B; Pehrson S; Pedersen OD; Køber L; Torp-Petersen C
    Expert Opin Drug Saf; 2004 Nov; 3(6):559-77. PubMed ID: 15500415
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment.
    Kühlkamp V; Mewis C; Suchalla R; Mermi J; Dörnberger V; Seipel L
    Int J Cardiol; 1999 Jun; 69(3):271-9. PubMed ID: 10402110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits.
    Frommeyer G; Kaiser D; Uphaus T; Kaese S; Osada N; Rajamani S; Belardinelli L; Breithardt G; Eckardt L; Milberg P
    Heart Rhythm; 2012 Dec; 9(12):2051-8. PubMed ID: 23044390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
    Fitton A; Sorkin EM
    Drugs; 1993 Oct; 46(4):678-719. PubMed ID: 7506652
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential.
    Nair LA; Grant AO
    Cardiovasc Drugs Ther; 1997 Apr; 11(2):149-67. PubMed ID: 9140692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanisms underlying the QT interval-prolonging effects of sevoflurane and its interactions with other QT-prolonging drugs.
    Kang J; Reynolds WP; Chen XL; Ji J; Wang H; Rampe DE
    Anesthesiology; 2006 May; 104(5):1015-22. PubMed ID: 16645454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs.
    Gwilt M; Blackburn KJ; Burges RA; Higgins AJ; Milne AA; Solca AM
    Eur J Pharmacol; 1992 May; 215(2-3):137-44. PubMed ID: 1396982
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug-induced post-repolarization refractoriness as an antiarrhythmic principle and its underlying mechanism.
    Franz MR; Gray RA; Karasik P; Moore HJ; Singh SN
    Europace; 2014 Nov; 16 Suppl 4():iv39-iv45. PubMed ID: 25362169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What niche will newer class III antiarrhythmic drugs occupy?
    Singh BN; Sarma JS
    Curr Cardiol Rep; 2001 Jul; 3(4):314-23. PubMed ID: 11406090
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proarrhythmic effects of DL- and D-sotalol on the "border zone" between normal and ischemic regions of isolated ventricular myocardium and antiarrhythmic effects on reperfusion.
    Picard S; Rouet R; Monti F; Puddu PE; Ducouret P; Flais F; Libersa C; Gérard JL
    J Cardiovasc Pharmacol; 1998 Jan; 31(1):126-39. PubMed ID: 9456287
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiarrhythmic drugs: present and future.
    Sharma S
    J Assoc Physicians India; 2007 Apr; 55 Suppl():43-6. PubMed ID: 18368867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiarrhythmic agents and proarrhythmia.
    Chaudhry GM; Haffajee CI
    Crit Care Med; 2000 Oct; 28(10 Suppl):N158-64. PubMed ID: 11055685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.